<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466671</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000031412</org_study_id>
    <nct_id>NCT03466671</nct_id>
  </id_info>
  <brief_title>A Trial of TTA-121 on Autism Spectrum Disorder</brief_title>
  <official_title>An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamamatsu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism
      spectrum disorder, and To compare effect sizes of different doses
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy on autism spectrum social core symptom assessed by social reciprocity score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in social reciprocity score (range: 0-14, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by communication score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in communication score (range: 0-8, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by revised algorithm score of social affect on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in revised algorithm score of social affect (range: 0-20, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on autism spectrum core symptom assessed by revised algorithm of repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in revised algorithm of repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Clinical Global Impression-Improvement</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Clinical Global Impression-Improvement (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Clinical Global Impression-Severity</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Clinical Global Impression-Severity (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Global Assessment of Functioning</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration</time_frame>
    <description>Changes in Global Assessment of Functioning (range: 1-100, Higher value represent a better outcome) between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by gaze fixation time on social region</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 60 min after the last drug administration</time_frame>
    <description>Changes in gaze fixation time on social region during being talked between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by quantitative analysis of facial expression</measure>
    <time_frame>At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration</time_frame>
    <description>Changes in quantitative measure of facial expression on videos recorded during ADOS administration between baseline and endpoint of each administration period</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Low dose once per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose twice per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose once per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose twice per day and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and low dose once per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and low dose twice per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and high dose once per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and high dose twice per day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTA-121</intervention_name>
    <description>A nove intranasal spray of oxytocin and placebo</description>
    <arm_group_label>Low dose once per day and placebo</arm_group_label>
    <arm_group_label>Low dose twice per day and placebo</arm_group_label>
    <arm_group_label>High dose once per day and placebo</arm_group_label>
    <arm_group_label>High dose twice per day and placebo</arm_group_label>
    <arm_group_label>Placebo and low dose once per day</arm_group_label>
    <arm_group_label>Placebo and low dose twice per day</arm_group_label>
    <arm_group_label>Placebo and high dose once per day</arm_group_label>
    <arm_group_label>Placebo and high dose twice per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of autism spectrum disorder based on Diagnostic and Statistical Manual of
             Mental Disorders-V with score exceeding the cut-off value of 10 for qualitative
             abnormalities in social reciprocity on Autism Diagnostic Interview Revised (ADIR)

          2. Full scale Intelligent quotient above 80 as measured using the Wechsler Adult
             Intelligent Scale-III

          3. Written informed consent for participating the trial

        Exclusion Criteria:

          1. Diagnosis of bipolar disorder or schizophrenia spectrum disorder

          2. Primary diagnosis of depressive disorders, obsessive-compulsive and related disorders,
             anxiety disorders, trauma- and stressor-related disorders, dissociative disorders,
             somatic symptom and related disorders, or neurodevelopmental disorders other than
             autism spectr um disorder

          3. Instability in symptoms of comorbid mental disorders such as depressive disorders or
             anxiety disorders

          4. History of changes in medication or doses of psychotropics within one month before
             registration

          5. Current treatment with more than one psychotropics

          6. History of hyper-sensitivity to oxytocin

          7. History of seizures or traumatic brain injury with loss of consciousness for longer
             than 5 minutes

          8. History of alcohol-related disorders, substance abuse, or addiction

          9. Family history of male breast cancer

         10. Subject who has severe complications

         11. Known hypersensitivity to some drugs and foods

         12. Subject who is not able to consent contraception during study period

         13. Participation in another registration clinical trial and administration of
             investigational drug during 120 days before informed consent

         14. Other Subjects whom a lead investigator or the patient's primary physician deems are
             not appropriate for this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidenori Yamasue, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Hamamatsu University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hidenori Yamasue, MD, PhD</last_name>
    <phone>+81-53-435-2295</phone>
    <email>yamasue@hama-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidenori Yamasue, MD, PhD</last_name>
      <phone>+81-53-435-2008</phone>
      <email>hm.TTA-121@hama-med.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamamatsu University</investigator_affiliation>
    <investigator_full_name>Hidenori Yamasue, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

